Alcoholic Hepatitis - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Alcoholic Hepatitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Alcoholic Hepatitis - Pipeline Review, H2 2016', provides an overview of the Alcoholic Hepatitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis
- The report reviews pipeline therapeutics for Alcoholic Hepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Alcoholic Hepatitis therapeutics and enlists all their major and minor projects
- The report assesses Alcoholic Hepatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Alcoholic Hepatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding  Alcoholic Hepatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Alcoholic Hepatitis Overview 7
Therapeutics Development 8
Pipeline Products for Alcoholic Hepatitis - Overview 8
Pipeline Products for Alcoholic Hepatitis - Comparative Analysis 9
Alcoholic Hepatitis - Therapeutics under Development by Companies 10
Alcoholic Hepatitis - Therapeutics under Investigation by Universities/Institutes 11
Alcoholic Hepatitis - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Alcoholic Hepatitis - Products under Development by Companies 14
Alcoholic Hepatitis - Products under Investigation by Universities/Institutes 15
Alcoholic Hepatitis - Companies Involved in Therapeutics Development 16
Alfact Innovation 16
Conatus Pharmaceuticals Inc. 17
Generon (Shanghai) Corporation Ltd. 18
Genextra S.p.a. 19
Gilead Sciences, Inc. 20
GRI Bio, Inc. 21
Immuron Limited 22
Promethera Biosciences S.A. 23
Verlyx Pharma Inc. 24
Alcoholic Hepatitis - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
ALF-5755 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
emricasan - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
F-652 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
GRI-0621 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
HepaStem - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
IMM-124E - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
obeticholic acid - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Oligonucleotide to Inhibit miRNA-155 for Alcoholic Liver Disease - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
pentamidine isethionate - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
PMKM-02GI1 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
selonsertib - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Alcoholic Hepatitis - Dormant Projects 63
Alcoholic Hepatitis - Product Development Milestones 64
Featured News & Press Releases 64
Sep 11, 2013: Conatus Pharmaceuticals Initiates Phase 2b Trial of Emricasan in Acute-on-Chronic Liver Failure Patients 64
Sep 10, 2013: Conatus Pharmaceuticals' Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population 64
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables

Number of Products under Development for Alcoholic Hepatitis, H2 2016 8
Number of Products under Development for Alcoholic Hepatitis - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Alcoholic Hepatitis - Pipeline by Alfact Innovation, H2 2016 16
Alcoholic Hepatitis - Pipeline by Conatus Pharmaceuticals Inc., H2 2016 17
Alcoholic Hepatitis - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016 18
Alcoholic Hepatitis - Pipeline by Genextra S.p.a., H2 2016 19
Alcoholic Hepatitis - Pipeline by Gilead Sciences, Inc., H2 2016 20
Alcoholic Hepatitis - Pipeline by GRI Bio, Inc., H2 2016 21
Alcoholic Hepatitis - Pipeline by Immuron Limited, H2 2016 22
Alcoholic Hepatitis - Pipeline by Promethera Biosciences S.A., H2 2016 23
Alcoholic Hepatitis - Pipeline by Verlyx Pharma Inc., H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Alcoholic Hepatitis - Dormant Projects, H2 2016 63